Philip Meuleman

List of Publications by Year in Descending Order

103 papers	5,078 citations	42 h-index	68 g-index
115 ext. papers	5,697 ext. citations	7.6 avg, IF	5.19 L-index

#	Paper	IF	Citations
103	Study of Hepatitis E Virus-4 Infection in Human Liver-Chimeric, Immunodeficient, and Immunocompetent Mice.. *Frontiers in Microbiology*, **2022**, 13, 819877	5.7	
102	Blocking Entry of Hepatitis B and D Viruses to Hepatocytes as a Novel Immunotherapy for Treating Chronic Infections. *Journal of Infectious Diseases*, **2021**, 223, 128-138	7	3
101	A Role for B Cells to Transmit Hepatitis C Virus Infection.. *Frontiers in Immunology*, **2021**, 12, 775098	8.4	
100	Liver-expressed and limit hepatitis C virus cross-species transmission to mice. *Science Advances*, **2020**, 6,	14.3	9
99	Expansion, in vivo-ex vivo cycling, and genetic manipulation of primary human hepatocytes. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 1678-1688	11.5	21
98	Inflammation Alters the Secretome and Immunomodulatory Properties of Human Skin-Derived Precursor Cells. *Cells*, **2020**, 9,	7.9	5
97	Robust hepatitis E virus infection and transcriptional response in human hepatocytes. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 1731-1741	11.5	29
96	Updates in Hepatitis E virus (HEV) field; lessons learned from human liver chimeric mice. *Reviews in Medical Virology*, **2020**, 30, e2086	11.7	12
95	Experimental Variables that Affect Human Hepatocyte AAV Transduction in Liver Chimeric Mice. *Molecular Therapy - Methods and Clinical Development*, **2020**, 18, 189-198	6.4	10
94	Animal Models for Hepatitis E virus. *Viruses*, **2019**, 11,	6.2	13
93	Hepatitis E virus prevalence in Flemish blood donors. *Journal of Viral Hepatitis*, **2019**, 26, 1218-1223	3.4	5
92	New insights into the ORF2 capsid protein, a key player of the hepatitis E virus lifecycle. *Scientific Reports*, **2019**, 9, 6243	4.9	22
91	Hepatitis E Virus (HEV) Open Reading Frame 2 Antigen Kinetics in Human-Liver Chimeric Mice and Its Impact on HEV Diagnosis. *Journal of Infectious Diseases*, **2019**, 220, 811-819	7	13
90	A central hydrophobic E1 region controls the pH range of hepatitis C virus membrane fusion and susceptibility to fusion inhibitors. *Journal of Hepatology*, **2019**, 70, 1082-1092	13.4	12
89	Infectivity and stability of hepatitis C virus in different perfusion solutions. *Transplant Infectious Disease*, **2019**, 21, e13135	2.7	1
88	Hepatitis E Virus Lifecycle and Identification of 3 Forms of the ORF2 Capsid Protein. *Gastroenterology*, **2018**, 154, 211-223.e8	13.3	85
87	The natural compound silvestrol inhibits hepatitis E virus (HEV) replication in vitro and in vivo. *Antiviral Research*, **2018**, 157, 151-158	10.8	42

86	Functional Study of the C-Terminal Part of the Hepatitis C Virus E1 Ectodomain. *Journal of Virology*, **2018**, 92,	6.6	3
85	Animal Models to Study Hepatitis C Virus Infection. *Frontiers in Immunology*, **2018**, 9, 1032	8.4	23
84	Development and characterization of a human monoclonal antibody targeting the N-terminal region of hepatitis C virus envelope glycoprotein E1. *Virology*, **2018**, 514, 30-41	3.6	4
83	Absence of zoonotic hepatitis E virus infection in Flemish dairy cows. *International Journal of Food Microbiology*, **2018**, 281, 54-59	5.8	16
82	Methylene Blue Treatment of Grafts During Cold Ischemia Time Reduces the Risk of Hepatitis C Virus Transmission. *Journal of Infectious Diseases*, **2018**, 218, 1711-1721	7	8
81	Tracking HCV protease population diversity during transmission and susceptibility of founder populations to antiviral therapy. *Antiviral Research*, **2017**, 139, 129-137	10.8	4
80	Transmission of hepatitis E virus infection to human-liver chimeric FRG mice using patient plasma. *Antiviral Research*, **2017**, 141, 150-154	10.8	34
79	Study of hepatitis E virus infection of genotype 1 and 3 in mice with humanised liver. *Gut*, **2017**, 66, 920-929	19.2	85
78	A novel neutralizing human monoclonal antibody broadly abrogates hepatitis C virus infection in vitro and in vivo. *Antiviral Research*, **2017**, 148, 53-64	10.8	12
77	Pentagalloylglucose, a highly bioavailable polyphenolic compound present in Cortex moutan, efficiently blocks hepatitis C virus entry. *Antiviral Research*, **2017**, 147, 19-28	10.8	18
76	Successful Engraftment of Human Hepatocytes in uPA-SCID and FRG KO Mice. *Methods in Molecular Biology*, **2017**, 1506, 117-130	1.4	13
75	Murine Tissues of Human Liver Chimeric Mice Are Not Susceptible to Hepatitis E Virus Genotypes 1 and 3. *Journal of Infectious Diseases*, **2017**, 216, 919-920	7	18
74	Host cell mTORC1 is required for HCV RNA replication. *Gut*, **2016**, 65, 2017-2028	19.2	42
73	Targeting a host-cell entry factor barricades antiviral-resistant HCV variants from on-therapy breakthrough in human-liver mice. *Gut*, **2016**, 65, 2029-2034	19.2	16
72	Tuning a cellular lipid kinase activity adapts hepatitis C virus to replication in cell culture. *Nature Microbiology*, **2016**, 2, 16247	26.6	39
71	Identification of a New Benzimidazole Derivative as an Antiviral against Hepatitis C Virus. *Journal of Virology*, **2016**, 90, 8422-34	6.6	24
70	Expanding the Host Range of Hepatitis C Virus through Viral Adaptation. *MBio*, **2016**, 7,	7.8	8
69	Metabolic studies of prostanozol with the uPA-SCID chimeric mouse model and human liver microsomes. *Steroids*, **2016**, 107, 139-48	2.8	

68	HVR1-mediated antibody evasion of highly infectious in vivo adapted HCV in humanised mice. *Gut*, **2016**, 65, 1988-1997	19.2	32
67	Apolipoprotein E Mediates Evasion From Hepatitis C Virus Neutralizing Antibodies. *Gastroenterology*, **2016**, 150, 206-217.e4	13.3	52
66	Mouse Systems to Model Hepatitis C Virus Treatment and Associated Resistance. *Viruses*, **2016**, 8,	6.2	14
65	Monoclonal anti-envelope antibody AP33 protects humanized mice against a patient-derived hepatitis C virus challenge. *Hepatology*, **2016**, 63, 1120-34	11.2	26
64	Flunarizine prevents hepatitis C virus membrane fusion in a genotype-dependent manner by targeting the potential fusion peptide within E1. *Hepatology*, **2016**, 63, 49-62	11.2	53
63	Polyphenols Inhibit Hepatitis C Virus Entry by a New Mechanism of Action. *Journal of Virology*, **2015** , 89, 10053-63	6.6	86
62	Clearance of persistent hepatitis C virus infection in humanized mice using a claudin-1-targeting monoclonal antibody. *Nature Biotechnology*, **2015**, 33, 549-554	44.5	104
61	The emergence of hepatitis E virus in Europe. *Future Virology*, **2015**, 10, 763-778	2.4	17
60	Animal models for the study of HCV. *Current Opinion in Virology*, **2015**, 13, 67-74	7.5	23
59	Assessment of Parasite Liver-Stage Burden in Human-Liver Chimeric Mice. *Methods in Molecular Biology*, **2015**, 1325, 59-68	1.4	6
58	Is hepatitis E virus an emerging problem in industrialized countries?. *Hepatology*, **2015**, 62, 1883-92	11.2	77
57	Generation and characterization of small single domain antibodies inhibiting human tumor necrosis factor receptor 1. *Journal of Biological Chemistry*, **2015**, 290, 4022-37	5.4	53
56	Anti-CD81 but not anti-SR-BI blocks Plasmodium falciparum liver infection in a humanized mouse model. *Journal of Antimicrobial Chemotherapy*, **2015**, 70, 1784-7	5.1	21
55	Combined adenovirus vector and hepatitis C virus envelope protein prime-boost regimen elicits T cell and neutralizing antibody immune responses. *Journal of Virology*, **2014**, 88, 5502-10	6.6	45
54	Turmeric curcumin inhibits entry of all hepatitis C virus genotypes into human liver cells. *Gut*, **2014**, 63, 1137-49	19.2	119
53	Successful anti-scavenger receptor class B type I (SR-BI) monoclonal antibody therapy in humanized mice after challenge with HCV variants with in vitro resistance to SR-BI-targeting agents. *Hepatology*, **2014**, 60, 1508-18	11.2	43
52	Metabolism of methylstenbolone studied with human liver microsomes and the uPA+/+-SCID chimeric mouse model. *Biomedical Chromatography*, **2014**, 28, 974-85	1.7	14
51	Sporozoite immunization of human volunteers under chemoprophylaxis induces functional antibodies against pre-erythrocytic stages of Plasmodium falciparum. *Malaria Journal*, **2014**, 13, 136	3.6	68

50	Human but not mouse hepatocytes respond to interferon-lambda in vivo. *PLoS ONE*, **2014**, 9, e87906	3.7	38
49	Human skin-derived precursor cells are poorly immunogenic and modulate the allogeneic immune response. *Stem Cells*, **2014**, 32, 2215-28	5.8	14
48	HCV animal models and liver disease. *Journal of Hepatology*, **2014**, 61, S26-33	13.4	34
47	Vaccine-induced monoclonal antibodies targeting circumsporozoite protein prevent Plasmodium falciparum infection. *Journal of Clinical Investigation*, **2014**, 124, 140-4	15.9	104
46	Impact of lipids and lipoproteins on hepatitis C virus infection and virus neutralization. *World Journal of Gastroenterology*, **2014**, 20, 15975-91	5.6	14
45	A genetically attenuated malaria vaccine candidate based on P. falciparum b9/slarp gene-deficient sporozoites. *ELife*, **2014**, 3,	8.9	53
44	In vitro and in vivo metabolisms of 1-pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122). *Forensic Toxicology*, **2013**, 31, 212-222	2.6	24
43	In vivo and in vitro metabolism of the synthetic cannabinoid JWH-200. *Rapid Communications in Mass Spectrometry*, **2013**, 27, 2115-26	2.2	38
42	Thermostability of seven hepatitis C virus genotypes in vitro and in vivo. *Journal of Viral Hepatitis*, **2013**, 20, 478-85	3.4	14
41	Molecular detection and quantification of Plasmodium falciparum-infected human hepatocytes in chimeric immune-deficient mice. *Malaria Journal*, **2013**, 12, 430	3.6	16
40	Artemisinin analogues as potent inhibitors of in vitro hepatitis C virus replication. *PLoS ONE*, **2013**, 8, e81783	3.7	29
39	Hepatitis C virus infection and related liver disease: the quest for the best animal model. *Frontiers in Microbiology*, **2013**, 4, 213	5.7	30
38	A human monoclonal antibody targeting scavenger receptor class B type I precludes hepatitis C virus infection and viral spread in vitro and in vivo. *Hepatology*, **2012**, 55, 364-72	11.2	101
37	861 THE LECTIN GRIFFITHSIN HAS ANTIVIRAL ACTIVITY AGAINST HEPATITIS C VIRUS IN VITRO AND IN VIVO. *Journal of Hepatology*, **2012**, 56, S335-S336	13.4	2
36	Novel human SR-BI antibodies prevent infection and dissemination of HCV in vitro and in humanized mice. *Journal of Hepatology*, **2012**, 57, 17-23	13.4	64
35	Blocking HCV entry as potential antiviral therapy. *Future Virology*, **2012**, 7, 547-561	2.4	7
34	The Sin3a repressor complex is a master regulator of STAT transcriptional activity. *Proceedings of the National Academy of Sciences of the United States of America*, **2012**, 109, 12058-63	11.5	60
33	Discovery of (7R)-14-cyclohexyl-7-{[2-(dimethylamino)ethyl](methyl) amino}-7,8-dihydro-6H-indolo[1,2-e][1,5]benzoxazocine-11-carboxylic acid (MK-3281), a potent and orally bioavailable finger-loop inhibitor of the hepatitis C virus NS5B polymerase. *Journal of Medicinal Chemistry*, **2011**, 54, 289-301	8.3	56

32	In vivo evaluation of the cross-genotype neutralizing activity of polyclonal antibodies against hepatitis C virus. *Hepatology*, **2011**, 53, 755-62	11.2	99
31	The green tea polyphenol, epigallocatechin-3-gallate, inhibits hepatitis C virus entry. *Hepatology*, **2011**, 54, 1947-55	11.2	207
30	Hypervariable region 1 differentially impacts viability of hepatitis C virus strains of genotypes 1 to 6 and impairs virus neutralization. *Journal of Virology*, **2011**, 85, 2224-34	6.6	115
29	Griffithsin has antiviral activity against hepatitis C virus. *Antimicrobial Agents and Chemotherapy*, **2011**, 55, 5159-67	5.9	112
28	Development and application of hepatitis C reporter viruses with genotype 1 to 7 core-nonstructural protein 2 (NS2) expressing fluorescent proteins or luciferase in modified JFH1 NS5A. *Journal of Virology*, **2011**, 85, 8913-28	6.6	73
27	Lipoprotein lipase inhibits hepatitis C virus (HCV) infection by blocking virus cell entry. *PLoS ONE*, **2011**, 6, e26637	3.7	40
26	Challenge pools of hepatitis C virus genotypes 1-6 prototype strains: replication fitness and pathogenicity in chimpanzees and human liver-chimeric mouse models. *Journal of Infectious Diseases*, **2010**, 201, 1381-9	7	61
25	Viral entry and escape from antibody-mediated neutralization influence hepatitis C virus reinfection in liver transplantation. *Journal of Experimental Medicine*, **2010**, 207, 2019-31	16.6	118
24	Factors determining successful engraftment of hepatocytes and susceptibility to hepatitis B and C virus infection in uPA-SCID mice. *Journal of Hepatology*, **2010**, 53, 468-76	13.4	64
23	HCV animal models: a journey of more than 30 years. *Viruses*, **2009**, 1, 222-40	6.2	13
22	uPA+/+-SCID mouse with humanized liver as a model for in vivo metabolism of exogenous steroids: methandienone as a case study. *Clinical Chemistry*, **2009**, 55, 1783-93	5.5	48
21	Detection and characterization of a new metabolite of 17alpha-methyltestosterone. *Drug Metabolism and Disposition*, **2009**, 37, 2153-62	4	42
20	Production of infectious genotype 1b virus particles in cell culture and impairment by replication enhancing mutations. *PLoS Pathogens*, **2009**, 5, e1000475	7.6	105
19	The uPA(+/+)-SCID mouse with humanized liver as a model for in vivo metabolism of 4-androstene-3,17-dione. *Drug Metabolism and Disposition*, **2009**, 37, 2367-74	4	20
18	Combination of liquid-chromatography tandem mass spectrometry in different scan modes with human and chimeric mouse urine for the study of steroid metabolism. *Drug Testing and Analysis*, **2009**, 1, 554-67	3.5	31
17	Steroid metabolism in chimeric mice with humanized liver. *Drug Testing and Analysis*, **2009**, 1, 531-7	3.5	23
16	Detection and structural investigation of metabolites of stanozolol in human urine by liquid chromatography tandem mass spectrometry. *Steroids*, **2009**, 74, 837-52	2.8	52
15	The human liver-uPA-SCID mouse: a model for the evaluation of antiviral compounds against HBV and HCV. *Antiviral Research*, **2008**, 80, 231-8	10.8	105

14	Role of the hepatitis C virus core+1 open reading frame and core cis-acting RNA elements in viral RNA translation and replication. *Journal of Virology*, **2008**, 82, 11503-15	6.6	78
13	Polyclonal immunoglobulins from a chronic hepatitis C virus patient protect human liver-chimeric mice from infection with a homologous hepatitis C virus strain. *Hepatology*, **2008**, 47, 1846-55	11.2	114
12	Anti-CD81 antibodies can prevent a hepatitis C virus infection in vivo. *Hepatology*, **2008**, 48, 1761-8	11.2	182
11	Ultra-rapid cardiotoxicity of the hepatitis C virus protease inhibitor BILN 2061 in the urokinase-type plasminogen activator mouse. *Gastroenterology*, **2007**, 133, 1144-55	13.3	48
10	Cell culture adaptation of hepatitis C virus and in vivo viability of an adapted variant. *Journal of Virology*, **2007**, 81, 13168-79	6.6	138
9	Scavenger receptor BI and BII expression levels modulate hepatitis C virus infectivity. *Journal of Virology*, **2007**, 81, 3162-9	6.6	126
8	Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro. *Proceedings of the National Academy of Sciences of the United States of America*, **2006**, 103, 3805-9	11.5	375
7	Immune suppression uncovers endogenous cytopathic effects of the hepatitis B virus. *Journal of Virology*, **2006**, 80, 2797-807	6.6	48
6	Human hepatocytes secrete soluble CD14, a process not directly influenced by HBV and HCV infection. *Clinica Chimica Acta*, **2006**, 366, 156-62	6.2	28
5	Morphological and biochemical characterization of a human liver in a uPA-SCID mouse chimera. *Hepatology*, **2005**, 41, 847-56	11.2	301
4	A simple and rapid method to determine the zygosity of uPA-transgenic SCID mice. *Biochemical and Biophysical Research Communications*, **2003**, 308, 375-8	3.4	40
3	In vivo inhibition of anti-hepatitis B virus core antigen (HBcAg) immunoglobulin G production by HBcAg-specific CD4(+) Th1-type T-cell clones in a hu-PBL-NOD/SCID mouse model. *Journal of Virology*, **2001**, 75, 11449-56	6.6	14
2	Prevention of hepatitis B infections: vaccination and its limitations. *Acta Clinica Belgica*, **2001**, 56, 209-19	1.8	13
1	Murine IL-2 receptor beta chain blockade improves human leukocyte engraftment in SCID mice. *European Journal of Immunology*, **1998**, 28, 3221-30	6.1	31